NASDAQ:SILO Silo Pharma Q2 2026 Earnings Report $1.78 +0.01 (+0.28%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Silo Pharma EPS ResultsActual EPS-$0.76Consensus EPS -$0.32Beat/MissMissed by -$0.44One Year Ago EPSN/ASilo Pharma Revenue ResultsActual RevenueN/AExpected Revenue$0.02 millionBeat/MissN/AYoY Revenue GrowthN/ASilo Pharma Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsSilo Pharma's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Silo Pharma Earnings HeadlinesSilo Pharma Gets U.S. Patent Allowance For SPC-15 PTSD TreatmentSeptember 18, 2026 | rttnews.comSilo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd TreatmentSeptember 18, 2026 | marketscreener.comMThe Pentagon Has 120 Days to Solve This Critical Mineral ProblemChina controls roughly 80% of the world's tungsten supply, and new Pentagon sourcing restrictions take effect January 1. The U.S. hasn't mined tungsten domestically since 2015. A little-known Nasdaq company controls Severniy Katpar, one of the largest undeveloped tungsten deposits, with potential to supply 15% of global demand. Two U.S. agencies have floated up to $1.6 billion in financing support as tungsten prices climb as much as 900%.September 24 at 1:00 AM | The Tomorrow Investor (Ad)Silo Pharma Receives USPTO Notice of Allowance for SPC-15 Patent Covering Stress-Induced Behavioral Response PreventionSeptember 18, 2026 | quiverquant.comQSilo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property PortfolioSeptember 18, 2026 | globenewswire.comSilo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation ForumSeptember 9, 2026 | rttnews.comSee More Silo Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email. Email Address About Silo PharmaSilo Pharma (NASDAQ:SILO) is a developmental-stage biopharmaceutical company focused on developing novel therapeutics and drug-delivery technologies for patients with conditions that have limited treatment options. The company’s approach combines traditional pharmaceutical compounds with psychedelic-related therapies and proprietary delivery systems designed to improve dosing, treatment duration, and patient administration. Silo Pharma’s pipeline has included programs targeting conditions such as fibromyalgia, post-traumatic stress disorder, Alzheimer’s disease, and rheumatoid arthritis. Its development efforts have featured SP-26, an implantable, controlled-release ketamine formulation being evaluated for potential use in fibromyalgia, as well as other investigational programs involving ketamine, psychedelic compounds, and intranasal or localized drug-delivery technologies. The company conducts its research and development activities primarily through collaborations with academic and scientific partners. Silo Pharma is headquartered in the United States and remains focused on advancing its preclinical and clinical-stage pipeline rather than commercializing an established portfolio of marketed medicines. Eric Weisblum has served in a leadership role as the company’s chief executive officer.View Silo Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
